<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040999</url>
  </required_header>
  <id_info>
    <org_study_id>3475-412</org_study_id>
    <secondary_id>2016-003934-25</secondary_id>
    <secondary_id>MK-3475-412</secondary_id>
    <secondary_id>173640</secondary_id>
    <nct_id>NCT03040999</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)</brief_title>
  <official_title>A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of pembrolizumab given
      concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in
      participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The
      primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in
      combination with CRT with respect to event-free survival (EFS) per Response Evaluation
      Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">June 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>EFS is the time from the date of randomization to the date of first record of disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From time of first dose of study treatment until the end of follow-up (up to 5 years)</time_frame>
    <description>Number of participants experiencing any sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Discontinuations Due to AEs</measure>
    <time_frame>From time of first dose of study treatment until the end of treatment (up to 1 year)</time_frame>
    <description>Number of participants discontinuing study drug due to an AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health Status/Quality of Life (GHS/QoL)</measure>
    <time_frame>Prior to the first dose of study treatment (Baseline) and at the time of last follow-up (up to 5 years)</time_frame>
    <description>Change from baseline in GHS/QoL using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing, Speech, and Pain Symptoms</measure>
    <time_frame>Prior to the first dose of study treatment (Baseline) and at the time of last follow-up (up to 5 years)</time_frame>
    <description>Change from baseline in swallowing, speech, and pain symptoms using the EORTC Head and Neck Questionnaire (EORTC QLQ-H&amp;N35)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Cisplatin + CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Cisplatin + CRT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered as an intravenous (IV) infusion every 3 weeks (Q3W)</description>
    <arm_group_label>Pembrolizumab + Cisplatin + CRT</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline or dextrose solution administered as an IV infusion Q3W</description>
    <arm_group_label>Placebo + Cisplatin + CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100 mg/m^2 administered as an IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab + Cisplatin + CRT</arm_group_label>
    <arm_group_label>Placebo + Cisplatin + CRT</arm_group_label>
    <other_name>Platinol®</other_name>
    <other_name>Platinol®-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated Fractionation (AFX) Radiotherapy</intervention_name>
    <description>70 Gray (Gy) given in 35 fractions over 6 weeks</description>
    <arm_group_label>Pembrolizumab + Cisplatin + CRT</arm_group_label>
    <arm_group_label>Placebo + Cisplatin + CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Fractionation (SFX) Radiotherapy</intervention_name>
    <description>70 Gy given in 35 fractions over 7 weeks</description>
    <arm_group_label>Pembrolizumab + Cisplatin + CRT</arm_group_label>
    <arm_group_label>Placebo + Cisplatin + CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a pathologically proven new diagnosis of oropharyngeal p16 positive, oropharyngeal
             p16 negative, or larynx/hypopharynx/oral cavity (independent of p16) squamous cell
             carcinoma. Participants with oral cavity tumors need to have unresectable disease.
             Participants with multiple synchronous tumors are not eligible for the study.

          -  Has provided tissue for Programmed Cell Death Receptor Ligand 1 (PD-L1) biomarker
             analysis from a core or excisional biopsy. If an excisional or incisional biopsy has
             been performed, participants remain eligible for the study provided the residual
             disease meets the staging criteria required for the trial (e.g., excisional biopsy of
             a lymph node with residual T4 primary). Prior surgical debulking, including
             tonsillectomy, for the head and neck cancer under study is not allowed.

          -  Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed
             by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1

          -  Is eligible for definitive CRT and not considered for primary surgery based on
             investigator decision

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed
             within 10 days prior to receiving the first dose of study therapy

          -  Female participants of childbearing potential must have a negative urine or serum
             pregnancy test within 72 hours prior to receiving the first dose of study therapy

          -  Female and male participants of reproductive potential must agree to use adequate
             contraception throughout the study period and for up to 180 days after the last dose
             of study therapy

        Exclusion Criteria:

          -  Is currently participating or has participated in a study with an investigational
             agent or using an investigational device within 4 weeks of the first dose of study
             therapy

          -  Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1),
             anti-PD-L1, anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an
             agent directed to another co-inhibitory T-cell receptor or has previously participated
             in clinical studies with pembrolizumab

          -  Has received a live vaccine within 30 days prior to the first dose of study therapy

          -  Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as
             nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer

          -  Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical
             surgery for head and neck cancer under study

          -  Has not recovered from major surgery prior to starting study therapy

          -  Has known active Hepatitis B or C

          -  Has known history of Human Immunodeficiency Virus (HIV)

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of study
             therapy

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years. Replacement therapy is not considered a form of systemic treatment.

          -  Has history of a diagnosed and/or treated hematologic or primary solid tumor
             malignancy, unless in remission for at least 5 years prior to randomization

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Has had previous allogeneic tissue/solid organ transplant

          -  Has active infection requiring systemic therapy

          -  Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or
             radiotherapy or their analogs

          -  Is pregnant or breast feeding or expecting to conceive or father children throughout
             the study period and for up to 180 days after the last dose of study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center ( Site 0273)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0274)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-502-3081</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare ( Site 0254)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-521-3830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven ( Site 0256)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-7981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center ( Site 0260)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-942-8004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University ( Site 0264)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-278-0779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center ( Site 0281)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225-215-1129</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center ( Site 0285)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>508-856-3216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health Systems ( Site 0267)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-936-5281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute ( Site 0272)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-576-8994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Frontier Cancer Center ( Site 0286)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada ( Site 8004)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-952-1251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester - James P. Wilmot Cancer Center ( Site 0255)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>585-275-5823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc. ( Site 8003)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center ( Site 8000)</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Center - Anderson ( Site 0251)</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>484-503-4156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central ( Site 8002)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>512-427-9400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA ( Site 8001)</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6685</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System ( Site 0261)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-244-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0269)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-288-2048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates (Summit Cancer Centers) ( Site 0257)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-462-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital ( Site 0301)</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales (Australia)</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61287389736</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital Western Sydney Local Health District ( Site 0304)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298818421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women s Hospital ( Site 0302)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61736468111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital ( Site 0303)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61882222023</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre ( Site 0300)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61396561749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus - Universitatsklinikum Graz ( Site 0601)</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4331638583853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz ( Site 0603)</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4373276774828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg ( Site 0600)</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+43572552580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien ( Site 0602)</name>
      <address>
        <city>Vienna/Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4314040072750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc - Bruxelles ( Site 0651)</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227649457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 0650)</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg ( Site 0652)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216346903</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart Tilman-Service d'Oncologie Medicale ( Site 0654)</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3243667111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternite Sainte-Elisabeth ( Site 0653)</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281720531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Izabel - Santa Casa de Misericordia da Bahia ( Site 0006)</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133203319</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Regional Integrado de Oncologia ( Site 0002)</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+558532865934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao ( Site 0001)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133572296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre ( Site 0011)</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133596380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0003)</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551733216638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer de Sao Paulo - ICESP ( Site 0004)</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551138932632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP de Ribeirao Preto ( Site 0008)</name>
      <address>
        <city>Ribeirao Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551636022482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre ( Site 0063)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4035213093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute ( Site 0064)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>7804328771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre ( Site 0062)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre ( Site 0055)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Cancer Care ( Site 0052)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6139863614</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0051)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169462911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre ( Site 0061)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514934193464802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0057)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819346111014311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe ( Site 0151)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5744459753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0150)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573148883972</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica del Country ( Site 0155)</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5715300470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FN Brno. ( Site 0703)</name>
      <address>
        <city>Brno</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532233642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Hradec Kralove ( Site 0705)</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420495832316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc ( Site 0701)</name>
      <address>
        <city>Olomouc</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava ( Site 0702)</name>
      <address>
        <city>Ostrava</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420597372124</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2. LF UK a FN Motol ( Site 0704)</name>
      <address>
        <city>Praha 5</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224434700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce ( Site 0700)</name>
      <address>
        <city>Praha 8</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420266084516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard Laboratoire Mahe Meziani ( Site 0760)</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243399493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Francois Chenieux ( Site 0757)</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33555454800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud ( Site 0754)</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De Lorraine ( Site 0758)</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33383598461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0759)</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen ( Site 0801)</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+499318533405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Waldklinikum Gera GmbH ( Site 0802)</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49365282651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitares Cancer Center Hamburg - UCCH ( Site 0811)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741057122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover ( Site 0807)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495115322301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein-Campus Luebeck ( Site 0803)</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4945150042000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Munchen ( Site 0810)</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4989440074521</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Ulm ( Site 0804)</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4973150059548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam MC ( Site 0903)</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972502061161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Jerusalem ( Site 0902)</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972508946244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0904)</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9729378012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba MC ( Site 0901)</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302542</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center ( Site 0900)</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97527360734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0954)</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390594223252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi ( Site 0955)</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39552751835</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo ( Site 0952)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393204369893</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 0953)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390294379234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori ( Site 0950)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0951)</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903362</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 0350)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital ( Site 0351)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81117161161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center ( Site 0354)</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81789291151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital ( Site 0359)</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81878985111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center ( Site 0353)</name>
      <address>
        <city>Natori</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81223843151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 0358)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital ( Site 0352)</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81822575555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 0355)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical And Dental University ( Site 0356)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338136111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 0357)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital ( Site 0454)</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk Do</state>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82432697243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0453)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital ( Site 0455)</name>
      <address>
        <city>Daejeon</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82422807157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0450)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234103438</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0452)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep NWZ ( Site 1350)</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31725483326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum ( Site 1352)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31204444295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG ( Site 1351)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31503616161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center ( Site 1354)</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107041505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital &amp; Coast District Health Board - Wellington Hospital ( Site 0400)</name>
      <address>
        <city>Wellington</city>
        <state>Newtown</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+64278013077</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolnoslaskie Centrum Onkologii. ( Site 1001)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48504207560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny ( Site 1015)</name>
      <address>
        <city>Wieliszew</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48603936331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1005)</name>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48334984045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1007)</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48602788669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie ( Site 1010)</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48602720957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1008)</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48721295010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zachodniopomorskie Centrum Onkologii ( Site 1013)</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48512773620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie ( Site 1000)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225462208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.U. Vall de Hebron ( Site 1052)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals ( Site 1053)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 1051)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349133030007545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre ( Site 1054)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914692313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 1055)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria ( Site 1056)</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34952270497</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gral Universitario de Valencia ( Site 1050)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34963131800437635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Kaohsiung ( Site 0501)</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 0503)</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital ( Site 0505)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886225433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0500)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital ( Site 0504)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886287121212612</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital ( Site 0502)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886975368112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1103)</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905353067506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1102)</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905427212606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>YBU Ataturk Egitim ve Arastirma Hastanesi ( Site 1108)</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905555306271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1100)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327236113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medipol Hastanesi ( Site 1104)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325280486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hastanesi ( Site 1109)</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322642353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Tip Fakultesi ( Site 1106)</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327650185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Tip Fakultesi ( Site 1101)</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326441884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital NHS Foundation Trust ( Site 1206)</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441603287671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire ( Site 1202)</name>
      <address>
        <city>Stoke-On-Trent</city>
        <state>Staffordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441782672586</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital ( Site 1207)</name>
      <address>
        <city>Ipswich</city>
        <state>Suffolk</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441473702994</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 1204)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442033111742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew s Hospital ( Site 1205)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442034655237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Foundation Trust ( Site 1200)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078118311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1208)</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441772524892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust ( Site 1203)</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442381205057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust ( Site 1201)</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078118311</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Ukraine</country>
  </removed_countries>
  <link>
    <url>http://keynoteclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Programmed Cell Death Receptor 1 (PD-1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PD-L2)</keyword>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PDL2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

